Rising Cardiovascular Mortality in Prostate Cancer Paitents: Results From Surveillance, Epidemiology and End Results (SEER) Database

Document Type

Conference Proceeding

Publication Date

11-7-2023

Publication Title

Circulation

Abstract

Introduction: Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer related mortality. Advancement in therapy has led to improved survival among patients, however, there has been increased incidence of cardiovascular events among cancer survivors.

Objective To observe the trend of cardiovascular specific death rate among patient with prostate cancer as compared to death due to cancer

Methods: Patients with prostate cancer registered in SEER database from 2005 to 2020 were included. Prostate cancer specific mortality rate, cardiovascular (CV) specific mortality rate and all-cause mortality rate were analyzed using SEER*Stat version 8.4.1 software in the rate session. Joinpoint version 5.0.2 was used to create annual log-linear time trends.

Results: The study included 857,410 patients diagnosed with prostate cancer from 2005 to 2020. The average annual percentage change (AAPC) of prostate cancer showed decreased incidence by 2.8 % (95% CI 1.8% to 4.1%, p<0.05) from 2005 to 2020 with significant decrease in annual percent change (APC) from 2005 to 2014 by 4.9% (95% CI 2.9 % to 12.5, p<0.05). AAPC of prostate cancer specific mortality rate increased by 1.8% ( 95% CI 1.3% to 2.9%, p<0.05) from 2005 to 2020 with significant increase in APC by 2.4% (95% CI 1.3% to 9.2%, p<0.05) from 2005 to 2018. AAPC of CV specific mortality rate increased by 4.4% (95% CI 4.1% to 4.9%, p<0.05) from 2005 to 2020 with significant increase in APC by 7.1% (95% CI 6% to 9.2%, p<0.05) from 2005 to 2011 and 2.6% (95% CI 2% to 3.1%, p<0.05) from 2011 to 2020 (Figure 1).

Conclusions: Around 2009, the cardiovascular specific mortality rate became higher than cancer specific mortality rate among prostate cancer patients and this trend has been consistent since then. It highlights advancement in treatment which has increased survival from prostate cancer, however it has increased cardiovascular mortality in patients due to advancing age as well as direct toxicity of treatment

Volume

148

Issue

Suppl 1

First Page

A16139

Comments

American Heart Association Scientific Sessions, November 11-13, 2023, Philadelphia, PA

DOI

10.1161/circ.148.suppl_1.16139

Link to Full Text

Share

COinS